BFRI Reports $17.1M Q4 Rev, $4.6M Op Income, $6.4M Cash, Ameluz PDT FDA sNDA Accepted, Phase 3 AK Success, $3M Xepi Sale
Biofrontera Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $0.95
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS